Lands’ End Announces New Term Loan
Company Refinances Existing Term Loan New Loan Maturity In 2028 DODGEVILLE, Wis., Jan. 02, 2024 (GLOBE NEWSWIRE) — Lands’ End, […]
Coherus Announces U.S. Launch of LOQTORZI™
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in […]
urban-gro, Inc. Secures Design-Build Contract Valued at Approximately $20 Million
LAFAYETTE, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), an integrated professional services […]
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, […]
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development […]
Asia Pacific Wire & Cable Corporation Limited Reports Third Quarter 2023 Financial Results
TAIPEI, Taiwan, Jan. 02, 2024 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) (“APWC” or the […]
Jasper Therapeutics, Inc. Announces Reverse Stock Split
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on […]
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced […]
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on […]
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company […]
